News
NICE recommends Biomarin’s Vimizim for patients with rare life-limiting metabolic disorder
Elosulfase alfa – branded as Vimizin and made by BioMarin – is now the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition.